At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 144 enrolled
Drug / intervention
MK0249 +1 moredrug
Likely dose
MK0249 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating MK0249 and Comparator: Placebo (unspecified) for Alzheimer's Disease. Completed, enrolled 144 participants.
Detailed Summary
The purpose of this study is to test the efficacy and safety of an investigational medication for improving symptoms of Alzheimer's Disease. Subjects will receive either active medication or placebo for 28 days. Tests of memory, concentration will be included. Safety will be monitored using routine clinical and laboratory tests.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedJan 2007
Primary CompletionAug 2008
TodayJul 2026
First PostedJan 11, 2007
Enrollment StartNov 1, 2006
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.5 years ago
Interventions
MK0249drug
MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
Comparator: Placebo (unspecified)drug
MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period